Articles tagged with Cancer Medication
Gastrointestinal stroma tumors (GIST) are rare cancers that can be problematic to detect and treat. Researchers have identified the mutational drivers for GIST in the stomach and found a potential drug therapy, temozolomide, which showed promising results in treating patients with specific mutations.
A study from Linköping University found that the tumour-inhibiting gene TET2 is silenced in most cases of acute lymphoblastic leukemia (ALL) in children. The gene can be reactivated by treatment with an existing drug, 5-azacytidine, suggesting a targeted therapy for ALL in children.
Researchers have identified a new potential treatment for neuroblastoma by targeting the ALT mechanism, which is responsible for chemotherapy resistance. The study found that activating ATM kinase at telomeres promotes chemotherapy resistance in ALT neuroblastoma and suggests a cancer-specific approach to treating this disease.
A large retrospective analysis of 14,000 patients with colorectal cancer found that common blood-pressure drugs like ACE inhibitors and beta-blockers were associated with decreased mortality. Patients who took their blood-pressure drugs consistently were less likely to die from their cancer.
Researchers at SpheroFill are developing a unique oral drug delivery platform using microsphere technology, protecting drugs from degradation and enabling targeted release. This technology has the potential to improve medication compliance and delivery of sensitive biological drugs.
Researchers identified DSS1 as a critical protein in breast cancer progression and found that depleting it makes cancer cells more responsive to lower doses of anti-cancer drugs. This technique may reduce drug-induced side effects in breast cancer patients, providing a safer treatment option.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Researchers at the University of Huddersfield have developed a new approach to combat cancer treatment challenges by creating self-assembled drugs with high specificity towards human cancer cells. The breakthrough demonstrates unprecedented anti-cancer activity and selectivity in laboratory testing.
Researchers at Massachusetts General Hospital have identified two separate genetic alterations that enable triple-negative breast cancer cells to develop resistance to a highly effective drug. The findings could help improve therapy and prolong survival for patients with this aggressive form of breast cancer.
Researchers found that combining entinostat with immunotherapy boosted cancer remission in mice by increasing neoantigen-specific T cells. The combination therapy showed promise in the lab and is being tested in an ongoing clinical trial for people with advanced bladder cancer.
Researchers found that the drug Vismodegib altered tumor-associated macrophage metabolism, shifting them from immunosuppressive M2 macrophages to pro-inflammatory M1 macrophages. This shift led to a decrease in tumor-promoting properties and improved immune response.
Researchers found that some medications used to treat autoimmune rheumatic diseases can weaken the immune response to COVID-19 vaccines. Vaccination still induced an immune response in patients, but at a lower rate than in those without autoimmune diseases.
Fels and Fox Chase researchers found specific TET2 and DNMT3A mutations in leukemia patients that affect DNA repair pathways. These mutations make leukemia cells sensitive to PARP inhibitors, a type of targeted therapy, while others are resistant. The study aims to develop personalized therapies for patients with these mutations.
Researchers discovered that hypoxia induces regional variations in gene-expression patterns in pancreatic cancer, with specific subpopulations of cancer cells surviving under hypoxic conditions. These findings suggest a link between hypoxia and aggressive tumor behavior, highlighting the need for targeted treatments.
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.
Researchers at UVA Health System discovered that combining drug palbociclib with ruxolitinib could effectively treat myelofibrosis by preventing bone marrow scarring and improving blood cell counts. This potential new treatment offers a promising approach to devastating blood disorder.
A comprehensive molecular map of lung squamous cell carcinoma has identified potential new drug targets, including the gene NSD3, and highlighted immune regulation pathways that could help cancer evade immunotherapies. The study's findings have also revealed metabolic dysregulation and crosstalk between different cellular processes.
Researchers at UB aim to reduce unwanted toxicity in cancer treatments by combining antibody-drug conjugates with payload-binding selectivity enhancers. The five-year study may lead to safer and more effective treatments for 1.8 million US cancer patients.
A big data study from UNSW Sydney found that Australian cancer patients kept up their pharmaceutical treatments during last year's COVID-19 lockdowns. The researchers attribute the good news to relatively low rates of COVID-19 infections in Australia, which minimally impacted cancer treatment patterns.
A world-first study found that cancer patients receiving chemotherapy intravenously have more than double the risk of developing a blood clot or thrombosis if the vein is too small and the catheter occupies more than 45% of the vein. Researchers identified specific limits on catheter-to-vein ratios to reduce risks for cancer patients.
Researchers analyzed patient specimens and clinical trial data from thousands of patients to assess the importance of immune cell molecules called Fc gamma receptors (FCGRs) in the therapeutic efficacy of two antibody drugs. High levels of FCGR2B on tumor cells were found to prevent rituximab efficacy, while obinutuzumab was not impact...
A genetic variant in the TCERG1L gene has been identified as a risk factor for cisplatin-induced hearing loss in children with cancer, increasing the risk by three times. The finding could lead to predictive tests to inform treatment decisions and advance pediatric cancer care.
Researchers discovered how the H3K27M mutation causes diffuse midline glioma (DMG) and successfully reversed its effects with an EZH2 inhibitor. They call for clinical trials to begin, offering hope for improved treatments in the future.
A phase 2 clinical trial found that ibrutinib is a safe and effective treatment option for patients with relapsed or variant forms of hairy cell leukemia. The study, conducted at Ohio State University Wexner Medical Center, showed improved cancer control for this high-risk patient group.
Researchers discovered that AML cells regulate mutant IDH2 activity through a master regulator, FLT3, to control 2-HG production. This understanding allows for better treatment options with current IDH2-targeting medications.
The study found that cancer cells become less stiff after exposure to chemotherapy drugs, but the rate of stiffness change decreases under hypoxic conditions. Alteration in cytoskeletal structure influences overall cell functions, including signaling, communication, adhesion, transport, and tumor metastasis.
A McMaster-led study found that abelacimab prevents blood clots for up to a month after surgery, reducing the risk by about 80% compared to enoxaparin. The treatment also has potential to treat other cardiovascular conditions, such as stroke and deep-vein thrombosis.
Researchers developed patient-specific tumor organoids to test immunotherapy treatments for appendiceal cancer. The study found that various types of immunotherapies can achieve personalized results, identifying beneficial treatments while sparing patients from harmful side effects.
Scientists at Sinai Health discover that all cancers fall into two categories based on the presence or absence of YAP. This binary rule reveals different drug sensitivities and resistance in each classification, offering a new strategy for treating aggressive forms of cancer.
Zeynep Eroglu, MD, assistant member of the Cutaneous Oncology Department at Moffitt Cancer Center, received the 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute. The award recognizes outstanding clinical investigators working to improve cancer care.
The Zero Childhood Cancer Program, a precision medicine program, has received a $600k donation from The Lott to enhance research capabilities and provide personalized treatment plans to children with high-risk cancer. Over 70% of enrolled patients have shown a response, with some tumours stabilized or shrunk.
Researchers found that combining low-dose radiation with immunotherapy significantly boosts cancer eradication rates in mice. The treatment approach triggers the immune system to attack cancer cells, even when radiation alone is too weak to destroy them.
Researchers have developed a new type of nanocarrier that combines photothermal, chemo-therapy, and chemodynamic therapy to target and destroy cancer cells. The nanoclusters, which are responsive to near-infrared light, show a significant inhibitory effect on mouse tumor growth in vivo experiments.
Research found that adult patients under 65 had less trouble paying for medications, dental care, and delayed treatment due to cost. The ACA's key features, including the Health Insurance Marketplace, led to a significant decrease in financial burdens.
The Lewis Katz School of Medicine at Temple University has received a $1 million T32 predoctoral training grant from the National Institute of General Medical Sciences. The grant aims to provide students with opportunities for training in cell signaling, epigenetics, and genome maintenance.
A new study found that using an existing immunotherapy drug for late-stage kidney cancer at an earlier stage can reduce the risk of cancer returning by a third. The KEYNOTE study involved over 1000 patients and showed similar side effects to other cancer treatments.
Researchers have identified a new generation of anti-cancer drugs that target aggressive childhood brain tumors. The genetic map of these tumours has helped predict the effectiveness of existing drugs, including Ixabepilone, in treating medulloblastoma.
A recent study published by the European Society of Cardiology found that older patients with heart failure are less likely to receive recommended therapies and dosages compared to their younger counterparts. The study analyzed data from the Swedish Heart Failure Registry and found that age was independently associated with undertreatm...
A study at ECCMID identifies existing drugs that could be repurposed to treat gonorrhoea by targeting efflux pumps, which remove toxic compounds from bacterial cells. The research found 57 potential drug candidates, including dequalinium and doxorubicin, which may serve as lead compounds for new gonorrhea treatments.
Researchers at Tel-Aviv University have developed a targeted delivery system for RNA-based drugs that selectively targets diseased cells without harming healthy ones. The breakthrough has potential implications for various diseases, including blood cancers and inflammatory conditions.
Researchers have developed a chemical compound that produces a powerful oxygen reaction when exposed to light, selectively killing cancer cells while leaving surrounding tissue intact. The photodrug is currently in clinical trials for patients with recurring bladder cancer resistant to traditional therapies.
A 18-year follow-up study of babies born from treatments including ICSI and frozen embryo transfer found no increased cancer risk in ART-conceived offspring. The study compared outcomes between ART children and those conceived naturally or with fertility drugs, concluding that there is no overall increase in cancer risk for those born ...
A new approach to molecular drug design has yielded a highly promising bladder cancer treatment candidate that induces rapid shedding of tumour cells and results in significant tumour size reduction. The treatment shows potent effects on patients with non-muscle invasive bladder cancer, demonstrating safety without side effects.
A nationwide study evaluates a targeted intervention aimed at transforming e-cigarettes from a maintenance product to a tool for smoking cessation. The research shows that the intervention produced smoking abstinence rates about 5-10 percentage points higher than those who received no intervention.
Researchers found that HER3 gene mutations can amplify activity of a protein that spurs tumor growth in breast cancer. A new study suggests that targeting this protein may lead to more effective treatments for patients with both HER2 and HER3 mutations.
A new online database, TOPOGRAPH, has been developed to streamline the process of recommending therapeutic treatments in precision cancer medicine for Australian patients. The platform catalogues oncology research and provides personalized treatment recommendations based on genomic variations and biomarkers.
MADM technology has been expanded to enable the analysis of over 96% of mouse genes at the single-cell level. This breakthrough allows researchers to study disease progression, including cancer, and gain insights into gene function.
Researchers discovered that pancreatic cancer cells use a backup protein complex to survive when KRAS is blocked, allowing them to continue growing and dividing. This finding highlights the need for drugs that can target multiple molecules in cancer cells to improve treatment outcomes.
A large study of over 1.8 million women has found no link between fertility drugs and an increased risk of breast cancer. The research, published in Fertility and Sterility journal, provides reassurance to women seeking fertility treatments.
Researchers found novobiocin selectively killed tumor cells with abnormal BRCA1 or BRCA2 genes. The drug is effective even in tumors resistant to PARP inhibitors, which are a prime therapy for cancers with DNA-repair glitches.
Researchers identified a new class of POLQ inhibitors that specifically kill cancer cells with mutations in the BRCA genes while leaving healthy cells unharmed. The drugs show promise in treating cancers such as breast, ovarian, pancreatic, and prostate cancer with BRCA mutations.
Dr. Larson has been named recipient of the prestigious Paul C. Aebersold Award for his contributions to cancer imaging and radionuclide therapy. He is a world-renowned expert in radiopharmaceutical therapy and molecular imaging.
Researchers discovered a targeted drug, AT7519, effective in thwarting pancreatic tumors addicted to mutant KRAS gene. The study found that this CDK inhibitor selectively kills mutant KRAS-addicted cancer cells.
Scientists at Rockefeller University have identified a new class of therapeutics that destroy fibrolamellar tumor cells growing in mice. The team tested over 5,000 compounds to find these effective treatments, which could potentially transform the landscape of precision medicine by tailoring treatment options for individual patients
Researchers discovered that MAOIs can activate the immune system to shrink various types of tumors. The study found that MAOIs help block immune checkpoints and prevent tumor-associated macrophages from suppressing T cell activity.
Researchers at RUDN University developed an eco-friendly method to synthesize pyrrole and pyrazole derivatives, which exhibit fluorescent properties. The new process is safer, cheaper, and more efficient, generating a wide range of bioactive compounds with potential applications in medicine.
Researchers identified neutrophil elastase as a major anti-cancer protein that activates cell death pathways specifically in cancer cells. This discovery may lead to the development of first-in-class medicines that target cancer cells while sparing healthy tissues.
Duke University engineers developed a prototype X-ray scanner that can reveal molecular composition of objects, revolutionizing cancer surgery, pathology, drug inspection, and geology. The technology can accurately diagnose cancerous tissues and analyze pharmaceuticals in real-time.
A new study by Ludwig Institute researchers has developed a method to quickly identify potentially effective drug combinations for personalized cancer therapy. By using dynamic BH3 profiling, the team found specific metabolic dependencies in triple-negative breast cancer cells that could be targeted with existing drugs.
A team of researchers identifies how the cowpea mosaic plant virus is recognized by the immune system and strongly stimulates it to attack and eliminate cancerous tumors. The discovery opens the door for CPMV to be pursued as a new biological drug for treatment of cancer.